No Data
Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $30
Stifel analyst Stephen Willey maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and adjusts the target price from $27 to $30.According to TipRanks data, the analyst has a success rate of 42.1
Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating
Nurix Therapeutics (NRIX) has an average outperform rating and a price target range of $15 to $35, according to analysts polled by Capital IQ.Price: 23.45, Change: -0.37, Percent Change: -1.55
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 42.14% JP Morgan $31 → $34 Maintains Overweight 07/15/2024 29.6% Barclays $20 → $31 Maintains
Nurix Therapeutics Is Maintained at Overweight by Barclays
Nurix Therapeutics Is Maintained at Overweight by
Express News | Nurix Therapeutics Inc. : Morgan Stanley Raises Target Price to $15.00 From $14.00